Survodutide vs Tirzepatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Survodutide
Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. It pairs GLP-1's appetite suppression with glucagon-driven energy expenditure and hepatic fat oxidation — a mechanism especially promising for fatty-liver disease. It is not FDA-approved.
Full profileTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.
Full profile| Survodutide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | BI 456906, Glucagon/GLP-1 dual agonist, Zealand/Boehringer dual agonist | LY3298176, Mounjaro, Zepbound |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 0.3mg–6mg mg, once weekly subcutaneous | 2.5mg–15mg mg, Once weekly subcutaneous injection |
| Administration | Subcutaneous injection (weekly) | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (dose-dependent, during titration), Vomiting, Diarrhea, Decreased appetite | Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation |
| Cited sources | 2 references | 4 references |
Key differences
- Evidence level differs: Survodutide is investigational (in trials), while Tirzepatide is fda-approved.
- Administration: Survodutide — Subcutaneous injection (weekly); Tirzepatide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Frequency: Survodutide is typically once weekly subcutaneous; Tirzepatide is Once weekly subcutaneous injection.
- Research depth: this profile cites 2 sources for Survodutide vs 4 for Tirzepatide.
How each works
Survodutide
Survodutide activates both the glucagon receptor (increasing energy expenditure and liver fat oxidation) and the GLP-1 receptor (reducing appetite and slowing gastric emptying). Its Phase 3 SYNCHRONIZE-1 obesity trial met its primary endpoint with meaningful weight loss at 76 weeks, and survodutide holds FDA Breakthrough Therapy designation for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis. As of mid-2026 it remains investigational, with efficacy figures at the topline/conference stage.
Tirzepatide
The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.